HELSINGIN YLIOPISTO HELSINGFORS UNIVERSITET UNIVERSITY OF HELSINKI LÄÄKETIETEELLINEN TIEDEKUNTA **MEDICINSKA FAKULTETEN FACULTY OF MEDICINE**

> Ms. Hansika Velagapudi Haukilahden lukio, Espoo, Finland Hansika.Velagapudi@gmail.com

Dose-dependent Epigallocatechin Gallate Treatment in HeLa cells Suppressed the Pro-inflammatory Cytokine IL1A


BACKGROUND

Epigallocatechin gallate (EGCG) is a green tea polyphenol with antioxidant, anti-inflammatory, and anti-cancer properties (1,2). While previous studies have shown promising effects (3,4), its influence on gene expression related to inflammation and tumor suppression in HeLa cells, a human cervical cancer cell line, remains unclear.

To investigate this, I focused on three gene targets to assess EGCG's potential anti-inflammatory and tumorsuppressive effects:

- Interleukin-1-alpha (IL1A)
- Interleukin 6 (*IL6*)

IL1A and IL6 pro-inflammatory cytokines involved in immune responses and cancer progression (5-7)






Figure 1: Day 2 morphology pictures of HeLa cells that were cultured in the (a) 5µg/ml (b) 10µg/ml (c) 20µg/ml and (d) 40µg/ml EGCG concentrated media

qPCR analysis revealed gene-specific, dose-dependent effects of EGCG on IL1A, IL6, and TP53 expression in HeLa cells:

- \Box IL1A was slightly downregulated at 5 µg/ml (0.94fold) and more clearly suppressed at 10 μ g/ml (0.73fold), suggesting potential anti-inflammatory effects at higher doses.
- *IL6* was upregulated at $5 \mu g/ml$ (1.49-fold), possibly reflecting early stress signaling, but returned to baseline at 10 μ g/ml (1.03-fold).
- **TP53** was upregulated at $5 \mu g/ml$ (1.25-fold), activation of indicating tumor-suppressive mechanisms, while expression plateaued at 10 μ g/ml (1.01-fold).

These findings suggest that low-dose EGCG $(5 \mu g/ml)$ elicits more pronounced biological effects in HeLa cells, particularly through modulation of inflammation- and tumor-related gene expression.

 \succ TP53, tumor suppressor gene, a tumor suppressor gene that regulates cell cycle arrest and apoptosis (8).

METHODOLOGY


Cell culture: HeLa cells were cultured in minimum essential medium and treated with EGCG at 5, 10, 20, and 40 μ g/ml. Based on cell viability, 5 and 10 μ g/ml were used for gene expression analysis. DMSO served as a negative control.

Cellular morphology: It was assessed under a light microscope after 48 hours of EGCG treatment to evaluate cell viability.


Quantitative PCR (qPCR): Total RNA was extracted and converted into cDNA. qPCR was then performed to measure the expression levels of *IL1A*, *IL6*, and *TP53*. Expression was normalized to the housekeeping gene *PPIG*, due to its stable expression across all samples.

Data analysis: Relative gene expression changes were

Relative expression of IL1A a)



Conditions (DMSO, $5\mu g/ml$, 10 $\mu g/ml$)



CONCLUSIONS


- EGCG treatment altered gene expression in a concentration-dependent manner.
- \Box At 5 µg/ml, notable effects were observed:
- *TP53* and *IL6* expression increased
- *IL1A* expression decreased \succ
- At 10 μ g/ml, gene expression changes were weaker or absent.
- These findings suggest that low-dose EGCG may have anti-inflammatory and tumor-suppressive effects by modulating gene expression.
- Further studies are needed to explore its molecular mechanisms and therapeutic potential.

calculated using the $\Delta\Delta$ Ct method. All statistical analyses - relative fold change values of qPCR data and barplot visualizations were performed using R software.

RESULTS

Cell morphology images confirmed that $5 \mu g/ml$ and 10 µg/ml EGCG preserved cell viability, while higher concentrations (20 μ g/ml and 40 μ g/ml) visible cell stress and shrinkage as seen in Figure 1.

Conditions (DMSO, 5µg/ml, 10 µg/ml)



Conditions (DMSO, $5\mu g/ml$, 10 $\mu g/ml$)

Figure 2: Fold change of gene expression levels of **(a)** *IL1A*, **(b)** *IL6* and **(c)** *TP53* in HeLa cells treated with different EGCG concentrations along with DMSO.

REFERENCES

- Wanda C Reygaert. Green Tea Catechins: Their Use in Treating and Preventing Infectious Diseases.
- Daniela Mokra, Marta Joskova, Juraj Mokry. Therapeutic Effects of Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG) in Relation to Molecular Pathways Controlling Inflammation, Oxidative Stress, and Apoptosis.
- Brahma N Singh, Sharmila Shankar, Rakesh K Srivastava. Green tea catechin, epigallocatechin-3gallate (EGCG): mechanisms, perspectives and clinical applications.
- Guang-Jian Du, Zhiyu Zhang, Xiao-Dong Wen, Chunhao Yu, Tyler Calway, Chun-Su Yuan, Chong-Zhi Wang. Epigallocatechin Gallate (EGCG) Is the Most Effective Cancer Chemopreventive Polyphenol in Green Tea
- Jing Wen Chiu, Zuhairah Binte Hanafi, Lionel Chin Yong Chew, Yu Mei, Haiyan Liu. IL1a 5. Processing, Signaling and Its Role in Cancer Progression.
- Neeraj Kumari, B S Dwarakanath, Asmita Das, Anant Narayan Bhatt. Role of interleukin-6 in cancer 6. progression and therapeutic resistance.
- Shou Liu; Ji Shin Lee; Chunfa Jie; Min Ho Park; Yoichiro Iwakura; Yogin Patel; Mithil Soni; David Reisman; Hexin Chen
- Peter Kainz. The PCR plateau phase towards an understanding of its limitations Author links open overlay pane
- R Core Team, version 4.4.1.